Drug Profile
Tree pollen allergy immunotherapy - Bial
Alternative Names: BIA 162960Latest Information Update: 23 Sep 2015
Price :
$50
*
At a glance
- Originator Bial
- Developer BIAL
- Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Allergic rhinoconjunctivitis
Most Recent Events
- 23 Sep 2015 Discontinued - Phase-I for Allergic rhinoconjunctivitis in Portugal (Parenteral)
- 23 Sep 2015 Discontinued - Phase-I/II for Allergic rhinoconjunctivitis in Spain (Parenteral)
- 11 Oct 2012 Phase-I/II clinical trials in Allergic rhinoconjunctivitis in Spain (Parenteral)